GlassScriptPhysician profile
Samantha Lynn Davis
NPI 1992335863
$2,057.06
in general payments reported to CMS, 2019-2025
28 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $580 · 2022: $520 · 2024: $468 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $956.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $204.94 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $197.81 | 2021-2025 | Farxiga |
| Atricure, INC. | $184.05 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $176.56 | 2022-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $174.22 | 2022-2025 | |
| Medtronic, INC. | $171.44 | 2025 | Micra, Selectsecure, Azure Xt Dr Mri Surescan |
| Abiomed | $122.09 | 2021 | |
| Novo Nordisk INC | $120.77 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $117.07 | 2024-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.52 | 2021-2025 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $85.65 | 2021-2025 | Lynozyfic |
| Pfizer INC. | $70.16 | 2021-2022 | |
| Biotronik INC. | $42.48 | 2022 | |
| Baxter Healthcare | $37.56 | 2022 | |
| Janssen Pharmaceuticals, INC | $33.25 | 2022-2024 | Xarelto |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $24.64 | 2024 | Arcalyst |
| Abbott Laboratories | $21.75 | 2025 | Amplatzer Amulet |
| Medicure Pharma INC. | $21.54 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.38 | 2025 | |
| Cvrx, INC. | $17.98 | 2024 | Barostim Neo System |
| Kowa Pharmaceuticals America, INC. | $17.76 | 2022 | |
| Vital Connect, INC | $17.04 | 2024 | Vitalpatch Rtm |
| Kiniksa Pharmaceuticals, LTD. | $15.14 | 2021 | |
| Amryt Pharma Holdings LTD | $13.03 | 2021 | |
| Cardiva Medical, INC. | $12.61 | 2022 | |
| G Medical Diagnostic Services, INC. | $12.15 | 2022 | |
| Esperion Therapeutics, INC. | $11.42 | 2021 | |
| Amgen INC. | $11.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.